

Medivir presenting at the Redeye Fight Cancer Event 2026

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Redeye Fight Cancer Event 2026, January 21, at 13.30 CET.

CEO Jens Lindberg will present the upcoming randomized, controlled two-arm study with 40 patients in each arm. The objective of the study is to show that the Company's drug candidate fostrox in combination with lenvatinib is superior to lenvatinib alone in second-line liver cancer.

The presentation is live broadcasted and can be followed via the link; [HERE](#).

The presentation will be available after the meeting on Medivirs website; www.medivir.com.

For additional information, please contact;

Magnus Christensen
Chief Financial Officer
Medivir AB

M: +46 8 5468 3100

Email: Magnus.Christensen@medivir.com

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.